| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Paul A Vöhringer, Gabriele Sani, Sergio A Barroilhet, Yongcai Mao, S Nassir Ghaem. Lurasidone Efficacy in Mixed Depressive States: A Comparison of Standard Rating Scales to the Koukopoulos Mixed Depression Rating Scale. Journal of clinical psychopharmacology. vol 40. issue 5. 2021-06-02. PMID:32701901. |
lurasidone efficacy in mixed depressive states: a comparison of standard rating scales to the koukopoulos mixed depression rating scale. |
2021-06-02 |
2023-08-13 |
Not clear |
| Paul A Vöhringer, Gabriele Sani, Sergio A Barroilhet, Yongcai Mao, S Nassir Ghaem. Lurasidone Efficacy in Mixed Depressive States: A Comparison of Standard Rating Scales to the Koukopoulos Mixed Depression Rating Scale. Journal of clinical psychopharmacology. vol 40. issue 5. 2021-06-02. PMID:32701901. |
a new mood rating scale for mixed states of depression along with manic-like excitatory symptoms, the koukopoulos mixed depression rating scale (kmdrs), was assessed in a post hoc analysis of a randomized clinical trial of lurasidone versus placebo in major depressive disorder (mdd) with mixed features. |
2021-06-02 |
2023-08-13 |
Not clear |
| Donna Rolin, Jessica Whelan, Charles B Montan. Is it depression or is it bipolar depression? Journal of the American Association of Nurse Practitioners. vol 32. issue 10. 2021-05-26. PMID:33017361. |
cariprazine, fluoxetine/olanzapine, lurasidone, and quetiapine are approved to treat bipolar depression; only cariprazine and quetiapine are approved to treat both bipolar mania and depression. |
2021-05-26 |
2023-08-13 |
Not clear |
| Jun Ishigooka, Tadafumi Kato, Mari Miyajima, Kei Watabe, Takahiro Masuda, Katsuhiko Hagi, Teruhiko Higuch. Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study. Journal of affective disorders. vol 281. 2021-04-21. PMID:33321381. |
lurasidone in the long-term treatment of bipolar i depression: a 28-week open label extension study. |
2021-04-21 |
2023-08-13 |
Not clear |
| Jun Ishigooka, Tadafumi Kato, Mari Miyajima, Kei Watabe, Takahiro Masuda, Katsuhiko Hagi, Teruhiko Higuch. Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study. Journal of affective disorders. vol 281. 2021-04-21. PMID:33321381. |
lurasidone has demonstrated efficacy for short-term treatment of bipolar depression in a diverse ethnic population including japanese. |
2021-04-21 |
2023-08-13 |
Not clear |
| Annamaria Cattaneo, Matthew Suderman, Nadia Cattane, Monica Mazzelli, Veronica Begni, Carlo Maj, Ilari D'Aprile, Carmine M Pariante, Alessia Luoni, Alessandra Berry, Katharina Wurst, Leif Hommers, Katharina Domschke, Francesca Cirulli, Moshe Szyf, Andreas Menke, Marco A Riv. Long-term effects of stress early in life on microRNA-30a and its network: Preventive effects of lurasidone and potential implications for depression vulnerability. Neurobiology of stress. vol 13. 2021-03-17. PMID:33344724. |
long-term effects of stress early in life on microrna-30a and its network: preventive effects of lurasidone and potential implications for depression vulnerability. |
2021-03-17 |
2023-08-13 |
rat |
| Charles L Raison, Cynthia Siu, Andrei Pikalov, Michael Tocco, Antony Loebe. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. Brain, behavior, and immunity. vol 84. 2021-03-09. PMID:31857217. |
c-reactive protein and response to lurasidone treatment in children and adolescents with bipolar i depression: results from a placebo-controlled trial. |
2021-03-09 |
2023-08-13 |
Not clear |
| Charles L Raison, Cynthia Siu, Andrei Pikalov, Michael Tocco, Antony Loebe. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. Brain, behavior, and immunity. vol 84. 2021-03-09. PMID:31857217. |
this study sought to investigate associations between levels of high-sensitivity c-reactive protein (hscrp) prior to treatment and change in depressive symptoms and cognition in a short-term, double-blind, placebo-controlled study of lurasidone in children and adolescents with bipolar i depression. |
2021-03-09 |
2023-08-13 |
Not clear |
| Charles L Raison, Cynthia Siu, Andrei Pikalov, Michael Tocco, Antony Loebe. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. Brain, behavior, and immunity. vol 84. 2021-03-09. PMID:31857217. |
patients 10-17 years of age with a dsm-5 diagnosis of bipolar i depression were randomized to 6 weeks of double-blind treatment with flexibly dosed lurasidone (20-80 mg/day) (n = 173) or placebo (n = 170). |
2021-03-09 |
2023-08-13 |
Not clear |
| Charles L Raison, Cynthia Siu, Andrei Pikalov, Michael Tocco, Antony Loebe. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. Brain, behavior, and immunity. vol 84. 2021-03-09. PMID:31857217. |
these results suggest that young patients with bipolar depression with normal weight and higher levels of pre-treatment crp may show a greater placebo-adjusted improvement in depressive symptoms and cognitive performance when treated with lurasidone. |
2021-03-09 |
2023-08-13 |
Not clear |
| Charles L Raison, Cynthia Siu, Andrei Pikalov, Michael Tocco, Antony Loebe. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. Brain, behavior, and immunity. vol 84. 2021-03-09. PMID:31857217. |
if these findings are confirmed in future prospective studies, crp and bmi may prove to be useful diagnostic and predictive biomarkers in the treatment with lurasidone of children and adolescents with bipolar depression. |
2021-03-09 |
2023-08-13 |
Not clear |
| Hui Wang, Ling Xiao, Hui-Ling Wang, Gao-Hua Wan. Efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar I depression: A meta-analysis. Journal of affective disorders. vol 264. 2021-02-15. PMID:32056755. |
efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar i depression: a meta-analysis. |
2021-02-15 |
2023-08-13 |
Not clear |
| Hui Wang, Ling Xiao, Hui-Ling Wang, Gao-Hua Wan. Efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar I depression: A meta-analysis. Journal of affective disorders. vol 264. 2021-02-15. PMID:32056755. |
this meta-analysis aimed to evaluate the efficacy and side effects of lurasidone by comparing with placebo in bipolar i depression. |
2021-02-15 |
2023-08-13 |
Not clear |
| Mohammad Rafi, Chhaya Goyal, Pooja Reddy, Shrikanth Redd. Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression? Indian journal of psychological medicine. vol 40. issue 2. 2020-09-28. PMID:29962579. |
we present a case of a 29-year-old male patient who was hospitalized with thrombocytopenia (who grade-3 toxicity) (unlabeled) along with extrapyramidal disorder, gastritis, and hyperprolactinemia within 2-3 months of initiation of tablet lurasidone 80 mg/day (lurasid, intas pharmaceuticals) in bipolar depression. |
2020-09-28 |
2023-08-13 |
Not clear |
| Mohammad Rafi, Chhaya Goyal, Pooja Reddy, Shrikanth Redd. Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression? Indian journal of psychological medicine. vol 40. issue 2. 2020-09-28. PMID:29962579. |
thus, this case presents a strong probability of lurasidone to cause myelosuppression/bone marrow depression. |
2020-09-28 |
2023-08-13 |
Not clear |
| Vivek C Kirpekar, Abhijeet D Faye, Sudhir H Bhave, Rahul Tadke, Sushil Gawand. Lurasidone-induced anemia: Is there a need for hematological monitoring? Indian journal of pharmacology. vol 51. issue 4. 2020-03-13. PMID:31571715. |
lurasidone is a newer drug used for treating schizophrenia and depression in bipolar disorder. |
2020-03-13 |
2023-08-13 |
Not clear |
| Yu-Chih She. Treatment of acute bipolar depression. Ci ji yi xue za zhi = Tzu-chi medical journal. vol 30. issue 3. 2019-11-20. PMID:30069121. |
at present, there are only 3 approved drug treatments for acute bipolar depression: olanzapine/fluoxetine combination, quetiapine (immediate or extended release), and lurasidone (monotherapy or adjunctive to lithium or valproate). |
2019-11-20 |
2023-08-13 |
Not clear |
| Charles L Raison, Andrei Pikalov, Cynthia Siu, Joyce Tsai, Kenneth Koblan, Antony Loebe. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain, behavior, and immunity. vol 73. 2019-07-31. PMID:30102967. |
c-reactive protein and response to lurasidone in patients with bipolar depression. |
2019-07-31 |
2023-08-13 |
Not clear |
| Charles L Raison, Andrei Pikalov, Cynthia Siu, Joyce Tsai, Kenneth Koblan, Antony Loebe. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain, behavior, and immunity. vol 73. 2019-07-31. PMID:30102967. |
the objective of this study was to evaluate whether crp might similarly predict antidepressant responses to lurasidone in patients with bipolar i depression. |
2019-07-31 |
2023-08-13 |
Not clear |
| Charles L Raison, Andrei Pikalov, Cynthia Siu, Joyce Tsai, Kenneth Koblan, Antony Loebe. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain, behavior, and immunity. vol 73. 2019-07-31. PMID:30102967. |
elevated crp level prior to treatment was associated with an enhanced clinical response to lurasidone in patients with bipolar i depression. |
2019-07-31 |
2023-08-13 |
Not clear |